Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Tibor Keler

Anthony S. Marucci

Celldex Therapeutics, Inc.

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

GC Therapeutics harnesses an induced pluripotent stem cell (iPSC) cellular programming platform to improve patient access across various therapeutic areas, focusing on gastrointestinal, neurological, and immunological diseases.

GC Therapeutics

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Metric
Company Name	Celldex Therapeutics, Inc.	Eterna Therapeutics Inc.	GC Therapeutics
Symbol	CLDX	ERNA
MSH ID	COM:CELLDEX	COM:ETERNATX	COM:GC-TX
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage			Series A
Employee Count	160	8
Website	celldex.com	brooklynitx.com	gc-tx.com
LinkedIn	celldex-therapeutics
Founders

Metric
Market Cap	2.41B	9.90M
Enterprise Value
Monthly Web Traffic		270.57K	1.68K
Web Traffic Growth		0.55	-0.43
Valuation
Raised Capital			65M

Metric
Revenue	6.88M	68K
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.88M	-1.29M
EBITDA	-139.03M	-19.55M
Operating Income	-142.04M	-20.67M
Net Income	-141.43M	-21.67M
EPS	-2.92	-4.08
Diluted EPS	-2.92	-4.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.72	-5.88
Operating Profit Margin	-18.41	-135.73
EBITDA Margin	-20.20	-287.51
Net Profit Margin	-18.09	-147.65
Return on Equity	-0.26	15.58
Return on Assets	-0.17	-0.44
Return on Capital Employed	-0.17	-0.50

COM:CELLDEX

Celldex

Last Close

26.22

22/11 21:00

Market Cap

2.41B

Beta: -

Volume Today

662.65K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-15.31	-0.42
P/B Ratio	7.13	2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	483.69	192.73
EV Multiple	-11.72	2.09

Metric
Days Sales Outstanding	21.07	12.71K
Days Payables Outstanding		4.45K
Days Inventory Outstanding	0.00
Operating Cycle	443.09	2.28K
Cash Conversion Cycle	56.95	1.79K
Asset Turnover	0.01	0.00

Metric
Operating Cash Flow	-107.29M	-20.41M
Free Cash Flow	-109.11M	-20.43M
Cash Flow to Debt	-38.64	-0.38
Operating Cash Flow/Sales	-11.10	-101.81
Free Cash Flow Yield	-0.05	-2.54

Metric
Cash & Equivalents	34.81M	7.58M
Accounts Receivable	-2.28M	527K
Inventory
Goodwill		2.04M
Debt to Capitalization	0.01	2.84
Debt to Assets	0.01	0.79
Current Ratio	8.84	0.73
Quick Ratio	31.77	1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	4.85	28.90
R&D to Revenue	25.31	130.82
SG&A to Revenue	6.57	252.08